首页> 外文期刊>Hepatology: Official Journal of the American Association for the Study of Liver Diseases >100% SVR4 in HCV Genotype 1 Non-Cirrhotic Treatment-Naive or -Experienced Patients With the Combination of ABT-493 and ABT-530 for 8 Weeks (SURVEYOR-I)

【24h】

100% SVR4 in HCV Genotype 1 Non-Cirrhotic Treatment-Naive or -Experienced Patients With the Combination of ABT-493 and ABT-530 for 8 Weeks (SURVEYOR-I)

机译：HCV基因型1非肝硬化初治或有经验的ABT-493和ABT-530组合患者中100％SVR4连续8周（SURVEYOR-I）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Hepatology: Official Journal of the American Association for the Study of Liver Diseases》 |2015年第6期|共2页
作者
Poordad Fred; Felizarta Franco; Asatryan Armen; Hassanein Tarek I.; Aguilar Humberto I.; Lalezari Jacob P.; Overcash J. Scott; Ng Teresa; Liu Ran; Lin Chih-Wei; Mensa Federico J.; Kort Jens;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类消化系及腹部疾病;
关键词

相似文献

外文文献
中文文献
专利

1. 100% SVR4 in HCV Genotype 1 Non-Cirrhotic Treatment-Naive or -Experienced Patients With the Combination of ABT-493 and ABT-530 for 8 Weeks (SURVEYOR-I) [J] . Poordad Fred, Felizarta Franco, Asatryan Armen, Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2015,第6期

机译：HCV基因型1非肝硬化初治或有经验的ABT-493和ABT-530组合患者中100％SVR4连续8周（SURVEYOR-I）
2. Analysis of HCV Variants in the MAGELLAN-1 Part 1 Study: ABT-493 and ABT-530 Combination Therapy of Genotype 1-Infected Patients Who Had Failed Prior Direct Acting Antiviral-Containing Regimens [J] . Ng Teresa, Pilot-Matias Tami, Tripathi Rakesh, Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2016,第S1期

机译：Magellan-1第1部分的HCV变体分析：ABT-493和ABT-530组合治疗基因型1感染患者，其未发生含有含抗病毒方案的失败
3. Ledipasvir/Sofosbuvir Fixed-Dose Combination (LDV/SOF FDC) for 8 Weeks for Treatment-NaIve, Non-cirrhotic Hepatitis C Genotype 6 (HCV-6) and for 12 Weeks for Those With Cirrhosis and/or Prior Treatment Failure: An Open-Labeled Clinical Trial [J] . Nguyen Mindie H., Trinh Huy N., Do Son T., Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2016,第S1期

机译：ledipasvir / sofosbuvir固定剂组合（LDV / SOF FDC）8周用于治疗 - 幼稚，非肝硬化丙型肝炎基因型6（HCV-6）和肝硬化和/或先前治疗失败的人的12周：开放 - 标记的临床试验
4. Hepatitis C Virus Genotyping and Serum Anti-F Antibody Detection of HCV Patients in the South of Jiangsu Province of China [C] . Xiao-Zhao Deng, Yun Zhang, Zhen-Yu Diao, International Forum on Progress on Post-Genome Technologies(5'IFPT); 20070910-11; Suzhou(CN) . 2007

机译：苏南地区丙型肝炎患者丙型肝炎病毒基因分型和血清抗F抗体检测
5. Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection [O] . Eric J. Lawitz, William D. ORiordan, Armen Asatryan, 2016

机译：直接作用抗病毒药ABT-493和ABT-530联合三天单药治疗丙型肝炎病毒基因型1的有效抗病毒活性。
6. High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis [O] . Edward Gane, Fred Poordad, Stanley Wang, 2016

机译：HCV基因型1或3感染患者ABT-493和ABT-530治疗的高疗效和补偿肝硬化

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号